drugset / Trial / NCT02259972
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
To investigate the safety, tolerability, and pharmacokinetics incl. dose proportionality of BI 113823, as well as the relative bioavailability of PiB vs. tablet and tablet fasted vs. fed (food effect for the tablet).
Timeline
- Start
- 2010-01
- Primary completion
- 2010-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 113823 | Unknown | 5 mg | Oral |
| Subject | BI 113823 | Unknown | 800 mg | Oral |
Indications
No indication recorded.